Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice

Blood Cancer J. 2021 Feb 9;11(2):16. doi: 10.1038/s41408-021-00420-8.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Fusion Proteins, bcr-abl / antagonists & inhibitors
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Male
  • Middle Aged
  • Niacinamide / adverse effects
  • Niacinamide / analogs & derivatives*
  • Niacinamide / therapeutic use
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrazoles / adverse effects
  • Pyrazoles / therapeutic use*
  • Treatment Outcome
  • Young Adult

Substances

  • BCR-ABL1 fusion protein, human
  • Protein Kinase Inhibitors
  • Pyrazoles
  • asciminib
  • Niacinamide
  • Fusion Proteins, bcr-abl